Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study
| Autor: | Mario García-Carrasco, Cecilia Camacho-Alarcón, Alejandro Ruiz-Argüelles, Manuel Sandoval-Cruz, Claudia Mendoza-Pinto, Sergio Sanchez-Sosa, Aurelio López-Colombo, Javier Garcés-Eisele, Virginia Reyes-Núñez, Gustavo Jimenez-Brito, Beatriz Pérez-Romano |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Human leucocyte antigen
Pathology medicine.medical_specialty medicine.drug_class Recombinant Fusion Proteins Immunology Vitiligo Pilot Projects Disease Monoclonal antibody Biomarkers Pharmacological Mice Therapeutic approach medicine Animals Humans Immunology and Allergy Infusions Intravenous Th1-Th2 Balance CD20 biology business.industry Antibodies Monoclonal HLA-DR Antigens Original Articles Antigens CD20 medicine.disease Phenotype Clinical trial Treatment Outcome Disease Progression biology.protein business Follow-Up Studies |
| Zdroj: | Clinical and Experimental Immunology. 174:229-236 |
| ISSN: | 1365-2249 0009-9104 |
| DOI: | 10.1111/cei.12168 |
| Popis: | Summary Five patients with active disseminated vitiligo were given 1 g of a chimeric (murine/human) monoclonal antibody to CD20 in a single intravenous infusion and followed-up for 6 months. Three of the patients showed an overt clinical and histological improvement of the disease, one presented slight improvement and the remaining patient showed no changes. Improvement was neither associated with changes in laboratory parameters nor to a specific human leucocyte antigen D-related (HLA-DR) phenotype. We believe that these preliminary results are encouraging, and further clinical trials should be undertaken. An important aim should be the finding of a marker with a good response to this therapeutic approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |